Top 10 Finalist Nurses Announced for Inaugural Aster Guardians Global Nursing Award
Aster Guardians Global Nursing Award has just announced its top 10 finalists hailing from across the world. These nurses have been selected from over 24,000 nurses who applied from over 184 countries, through a stringent review process run independently by Ernst & Young LLP, a Screening Jury and a Grand Jury. All applications were evaluated to create a shortlist of 181 which underwent further review to put forward 41 top applications. These 41 applications were then reviewed by the Grand Jury to announce the top 10 finalists. All applicant nurses were asked to submit their applications based on four areas of contribution: Leadership, Research/Innovation, Patient Care and Society/Community Service.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220411005418/en/
The top 10 finalists, who will now undergo further evaluation to claim the grand prize of USD 250,000, are: Anna Qabale Duba from Kenya; Dida Jirma Bulle from Kenya; Francis Michael Fernando from United Kingdom; Jasmine Mohammed Sharaf from United Arab Emirates; Julia Dorothy Downing from United Kingdom; Lincy Padicala Joseph from India, Manju Dhandapani from India; Matthew James Ball from Australia; Rachel Abraham Joseph from United States and Wais Mohammad Qarani from Afghanistan. To know more about the top 10 finalists, please visit: https://www.asterguardians.com/.
Speaking on the top 10 finalists and the upcoming award ceremony to be held on 12th May – International Nurses Day, at The Atlantis, Dubai, Dr. Azad Moopen, Founder Chairman and Managing Director of Aster DM Healthcare said, “With over 7000 nurses as the main pillar of our organization, we at Aster witness their commitment and compassion every single day. During this pandemic, their critical contribution with dedication and sacrifice, putting their own safety and lives at risk, was brought to the forefront globally. We thought that it is appropriate to institute a global level award for the nurses to recognize the members of this noble profession. With over 24,000 nurses who applied, we are overwhelmed by the response received from different parts of the world for the inaugural edition of Aster Guardians Global Nursing Award. It has been a hard task for the eminent Jury members to shortlist the top 10 extraordinary nurses from the large number of applicants. We wish the finalists nominated in the top 10 all the very best for the final evaluation process.”
While one winner will be awarded the grand prize of USD 250,000, the other nine finalists will receive a monetary award. The final round will consist of public voting for each of the nurses starting from 26th April and in-person interview with the Grand Jury members consisting of Mr. Howard Catton - Chief Executive Officer, International Council of Nurses, Switzerland; Prof. Sheila Tlou - Co-Chairperson, Global HIV Prevention Coalition and Ex - Minister of Health & Member of Parliament – Govt. of Botswana; Prof. James Buchan - Adjunct Professor, WHO Collaborating Centre for Nursing; Mr. Muralee Thummarukudy, Acting Head, Resilience to Disasters and Conflicts Global Support Branch, United Nations Environment Programme, Switzerland; and Dr. Carolyn Gomes, Executive Director, Caribbean Vulnerable Communities Coalition (CVC), Jamaica.
About Aster DM Healthcare
Aster DM Healthcare Limited is one of the largest private healthcare service providers operating in GCC and in India. With an inherent emphasis on clinical excellence, we are one of the few entities in the world with a strong presence across primary, secondary, tertiary, and quaternary healthcare through our 27 hospitals, 118 clinics, 323 pharmacies and 66 labs & patient experience centres in seven countries, including India. We have over 24,350 plus dedicated staff including 3,110 doctors and 7,063 nurses across the geographies that we are present in, delivering a simple yet strong promise to our different stakeholders: "We'll treat you well."
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005418/en/
Contact information
Lavanya Mandal
Head of PR and Internal Communications, +971528126577
Email: lavanya.mandal@asterdmhealthcare.com
Facebook: https://www.facebook.com/AsterGuardians
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ireland Unveils Seven New Halloween Experiences30.10.2025 16:00:00 EET | Press release
With seven brand-new Halloween hubs or experiences launching across the island this month, Ireland has truly become the ultimate destination to celebrate Halloween in 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022209535/en/ Derry Halloween Festival, County Derry~Londonderry Ireland’s Halloween Season Rooted in the ancient Celtic festival of Samhain, Halloween originated in Ireland more than 2,000 years ago and, this year, the island of Ireland is expanding its celebration like never before. With over 340 events planned across the island to celebrate this year, Halloween in Ireland is fast becoming a bucket-list travel experience. Seven new Halloween hubs join existing flagship events across the island of Ireland including the Púca Festival in County Meath and Derry Halloween in Derry-Londonderry which together welcomed over 169,000 visitors last year. The seven new hubs are inviting visitors to come and explore
Staloral ® Birch Phase III Study Successfully Meets Primary Endpoint, Demonstrating Efficacy in Children and Adolescents30.10.2025 15:56:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, announced today that its Phase IIIb clinical study (YOBI, YOung patients and BIrch allergy), designed to confirm the safety and efficacy of Staloral® Birch in children and adolescents with birch pollen-induced allergic rhino-conjunctivitis (ARC), with or without asthma, has successfully achieved its primary endpoint. The trial enrolled 553 children aged 5 -17 years with moderate to severe birch pollen-induced ARC, with or without asthma, across 64 sites in 12 European countries and assessed the efficacy and safety of Staloral® birch 300IR daily maintenance dose administered pre-and co-seasonally over two consecutive birch pollen seasons. The YOBI study successfully met its primary endpoint, demonstrating the efficacy of Staloral® Birch in a paediatric population (5-17) with a 41% improvement in the ARC total combined score during the second pollen season compared to placebo. These results were highly statistically significant
Andersen Consulting Enhances Its Platform Through Collaboration With threon30.10.2025 15:30:00 EET | Press release
Andersen Consulting deepens its business transformation and digital transformation capabilities through a Collaboration Agreement with threon, a Belgium-based consultancy known for delivering pragmatic, end-to-end strategy execution support. For more than 20 years, threon has been a trusted advisor for organizations looking to turn big ideas into delivering true business impact. The firm brings together their expertise in strategic portfolio management, digital transformation, and executive training to help leaders move from vision to execution. Threon’s unique approach blends project delivery, workforce development, and smart software solutions, empowering teams to deliver faster, scale with confidence, and achieve lasting results. CEO of threon Tom Dedecker said, “We bring focus and peace to organizations, enabling faster decision-making and sustainable transformation rooted in their unique identity.” Eric Noerdinger, managing director of threon added, “Our goal is to embed change su
Bending Spoons Raises $710M for Continued Investment and Growth30.10.2025 15:00:00 EET | Press release
Bending Spoons, one of Europe’s leading technology companies, today announced it has raised $710 million in equity at a pre-money valuation of $11 billion. The round was led by accounts advised by T. Rowe Price Investment Management, Inc., with participation from Baillie Gifford, Cox Enterprises, Durable Capital Partners, Fidelity Management & Research Company, Foxhaven Asset Management, and Radcliff, among others. Goldman Sachs International acted as sole placement agent and Clifford Chance served as legal advisor to the transaction. Notarial advisory services were provided by ZNR Notai. “This moment is a validation of a decade’s worth of work and it serves as an important recognition of what we’ve accomplished at Bending Spoons so far. We remain early in our journey and have ambitious plans for continued investment and growth,” shares Luca Ferrari, co-founder and CEO of Bending Spoons. “We’re proud to bring on some of the world’s finest investors who believe in our approach to value
Debiopharm Forges AI-powered Alliance With NetTargets to Pioneer Dual-payload ADCs Against Drug-resistant Cancers30.10.2025 15:00:00 EET | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company dedicated to developing innovative therapies that respond to high unmet medical needs, today announced a strategic research collaboration with NetTargets (www.net-targets.com), a South Korean biotech company specializing in AI-enhanced systems biology for drug discovery, to rationally design and advance the discovery of novel, synergistic drug combinations for Debiopharm’s next-generation Antibody-Drug Conjugates (ADCs). This alliance unites NetTargets' sophisticated artificial intelligence (AI) platform with Debiopharm's proprietary MLINKtechnology to create a new paradigm in cancer treatment, aiming to deliver a decisive, dual-action blow against treatment-resistant tumors. This collaboration achieves this multi-pronged strategy by uniting two cutting-edge technologies: NetTargets' AI-Powered Discovery Engine and Debiopharm's MLINK Duo Technology. NetTargets' proprietary AI platform integrates
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom